Navigation Links
GenVec Reports Third Quarter 2009 Financial Results
Date:11/5/2009

GAITHERSBURG, Md., Nov. 5 /PRNewswire-FirstCall/ -- GenVec, Inc. (Nasdaq: GNVC) today announced its financial results for the third quarter ended September 30, 2009. GenVec reported a net loss of $3.6 million ($0.04 per share) for the three months ended September 30, 2009 compared to a net loss of $6.8 million ($0.08 per share) in the comparable quarter of 2008. For the nine months ended September 30, 2009, GenVec's net loss was $14.1 million ($0.15 per share), compared to a net loss of $19.6 million ($0.24 per share) for the nine months ended September 30, 2008.

(Logo: http://www.newscom.com/cgi-bin/prnh/20081205/DC50112LOGO )

Revenues for the three-month and nine-month periods ended September 30, 2009 were $2.9 million and $10.5 million, respectively, compared to revenues of $4.2 million and $11.8 million in the comparable prior year periods. For each period in 2009 we experienced decreased revenue under the FMD program due mainly to the scope of work performed compared to the prior year periods. We also had lower revenue under the malaria program for the nine-month period ended September 30, 2009 due mainly to the work performed under the new contract which did not begin until the second quarter of 2009. The decreases noted above were offset by an increase in revenue associated with our HIV program in the nine-month period ended September 30, 2009 due mainly to increased research, assay, and process development efforts as compared to the comparable prior year period.

Operating expenses were $6.5 million and $24.3 million for the three-month and nine-month periods ended September 30, 2009, respectively, representing decreases of 42 percent and 24 percent as compared to $11.2 million and $32.0 million in the comparable prior year perio
'/>"/>

SOURCE GenVec, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. GenVec Announces Registered Offering of $6 Million in Common Stock and Warrants
2. GenVec Expands Contract Supporting Malaria Vaccine Program
3. GenVec Reports Second Quarter 2009 Financial Results
4. GenVec Receives an Approximately $2.5 Million Grant to Support Novel Cell Line Development
5. GenVec Announces Registered Offering of $6 Million in Common Stock and Warrants
6. GenVec Announces Third Quarter 2009 Results Conference Call
7. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
8. QMed, Inc. Reports July Medicare SNP Enrollments
9. Phlo Affiliate Reports Expanded Coverage to Oregon Border
10. Healthcare Technologies Reports Loss for 2007 Second Quarter & Six Months Results
11. Dragon Pharmaceutical Reports Growth in Sales and Profits during Second Quarter of 2007
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/1/2015)... TORONTO , April 1, 2015 /PRNewswire/ - ... Securities Exchange: PBT.U), is pleased to announce that ... holds 54% equity, has entered into an agreement ... Biohaven,s first clinical trial with their lead compound ... the identification and development of clinical stage neuroscience ...
(Date:4/1/2015)... 2014 /CNW/ - Canada,s Research-Based Pharmaceutical ... newly released report on Cost Drivers of Public Drug Plans ... to the report, the rates of change in drug costs ... of -0.8 percent in 2012/13 for a number of select ... examines the costs of medicines without considering their overall impact ...
(Date:4/1/2015)... Los Angeles, CA (PRWEB) April 01, 2015 ... portable reader that can read both chromatographic and fluorescent ... a leading supplier of high performance, quantitative readers and ... readers globally. The HRDR-400 is a first of its ... capabilities in one instrument. , Dr. Neven Karlovac, ...
(Date:4/1/2015)... (PRWEB) April 01, 2015 National recruitment ... the placement of Brad Allen as Head of Sales ... the health system market. , Allen brings over ... and sales at a number of companies including Dell ... knowledge and experience were a perfect fit for accomplishing ...
Breaking Biology Technology:Portage's Biohaven Announces Agreement with inVentiv Health 2Portage's Biohaven Announces Agreement with inVentiv Health 3Rx&D responds to PMPRB report: overall impact of medicines must always be considered 2Holomic to Introduce the First Dual, Chromatographic and Fluorescent Rapid Test Reader, the HRDR-400 2Slone Partners Fills Head of Sales at Optimal Medicine 2
... , , , , , , ... CHBT ) ("China-Biotics", "the Company"), a leading Chinese firm,specializing in ... its financial results for,the third quarter of its 2010 fiscal year, ... Third Quarter 2010 Highlights, -- Net sales increased ...
... , NEW YORK , Feb. 10 ... Board: ILNS), a biopharmaceutical company focused on development of ... that several of its significant shareholders (the "Interested Shareholders") ... the Company and assist the Company in its efforts ...
... , SILVER SPRING, Md. , and ... a wholly-owned subsidiary of United Therapeutics Corporation (Nasdaq: UTHR ... Agreement with ImmuneWorks, Inc. to pursue development of ImmuneWorks, lead ... for the treatment of Idiopathic Pulmonary Fibrosis (IPF) and Primary ...
Cached Biology Technology:China-Biotics, Inc. Reports Third Quarter Fiscal 2010 Financial Results 2China-Biotics, Inc. Reports Third Quarter Fiscal 2010 Financial Results 3China-Biotics, Inc. Reports Third Quarter Fiscal 2010 Financial Results 4China-Biotics, Inc. Reports Third Quarter Fiscal 2010 Financial Results 5China-Biotics, Inc. Reports Third Quarter Fiscal 2010 Financial Results 6China-Biotics, Inc. Reports Third Quarter Fiscal 2010 Financial Results 7China-Biotics, Inc. Reports Third Quarter Fiscal 2010 Financial Results 8China-Biotics, Inc. Reports Third Quarter Fiscal 2010 Financial Results 9China-Biotics, Inc. Reports Third Quarter Fiscal 2010 Financial Results 10China-Biotics, Inc. Reports Third Quarter Fiscal 2010 Financial Results 11China-Biotics, Inc. Reports Third Quarter Fiscal 2010 Financial Results 12China-Biotics, Inc. Reports Third Quarter Fiscal 2010 Financial Results 13Intellect Neurosciences, Inc. Announces Preliminary Agreement with Significant Shareholders to Provide Interim Funding and Assist the Company in Efforts to Secure Additional Financing 2Intellect Neurosciences, Inc. Announces Preliminary Agreement with Significant Shareholders to Provide Interim Funding and Assist the Company in Efforts to Secure Additional Financing 3Intellect Neurosciences, Inc. Announces Preliminary Agreement with Significant Shareholders to Provide Interim Funding and Assist the Company in Efforts to Secure Additional Financing 4Lung Rx and ImmuneWorks Announce Collaboration in Idiopathic Pulmonary Fibrosis and Primary Graft Dysfunction 2Lung Rx and ImmuneWorks Announce Collaboration in Idiopathic Pulmonary Fibrosis and Primary Graft Dysfunction 3
(Date:3/31/2015)... , March 31, 2015   Guidepoint , a ... of the Post-Surgical Pain Management TRACKER, part of the ... usage trends in the medical device and therapeutics markets. ... data including treatment volumes, market share, and adoption rates ... associated with joint surgery. The Post-Surgical Pain ...
(Date:3/24/2015)... and Markets ( http://www.researchandmarkets.com/research/kvdtcw/face_and_voice ) has announced the addition ... Report" report to their offering. This report analyzes ... by the following Segments: Face Biometrics, and Voice Biometrics. The report ... , Japan , Europe , ... & Africa , and Latin America ...
(Date:3/23/2015)... --  HOYOS Labs , a leading global authentication infrastructure ... Company will demonstrate multiple biometrics-based technologies under its identity ... on March 23 through 25, 2015, in ... IEEE Biometric Open Protocol Standard; free biometrics-based consumer app, ... system. BOPS was invented by HOYOS Labs and contributed ...
Breaking Biology News(10 mins):Guidepoint Launches Post-Surgical Pain Management TRACKER 2Guidepoint Launches Post-Surgical Pain Management TRACKER 3Face and Voice Biometrics - Global Strategic Business Report 2015: Face Recognition Gains Prominence in Immigration Control 2Face and Voice Biometrics - Global Strategic Business Report 2015: Face Recognition Gains Prominence in Immigration Control 3Face and Voice Biometrics - Global Strategic Business Report 2015: Face Recognition Gains Prominence in Immigration Control 4Face and Voice Biometrics - Global Strategic Business Report 2015: Face Recognition Gains Prominence in Immigration Control 5Face and Voice Biometrics - Global Strategic Business Report 2015: Face Recognition Gains Prominence in Immigration Control 6HOYOS Labs to Showcase Host of Biometrics Technologies at Connect:ID in Washington, D.C. 2HOYOS Labs to Showcase Host of Biometrics Technologies at Connect:ID in Washington, D.C. 3
... release is available in German . ... has substantially increased around the world. As a team of ... Technical University of Dresden and the University of Freiburg headed ... temporal trends of global pollination benefit" in the open-access journal ...
... - Researchers at the Centre for Addiction and Mental Health ... form of intellectual disability, as well as how it likely ... Scientist Dr. John Vincent and his team found a mutation ... a finding to be published in the May issue of ...
... successful in attracting funding of an Alexander von Humboldt ... response to an application to appoint Professor Dr. Wolfram ... the USA, to the Center for Thrombosis and Hemostasis ... announced jointly by the Alexander von Humboldt Foundation and ...
Cached Biology News:Global prices of pollination-dependent products such as coffee could rise in the long term 2Global prices of pollination-dependent products such as coffee could rise in the long term 3New form of intellectual disability discovered 2Mainz University Medical Center attracts funding of Alexander von Humboldt Professorship 2Mainz University Medical Center attracts funding of Alexander von Humboldt Professorship 3